Brief: Psyence And Filament Health Enter Into Exclusive Licensing Agreement For Natural Psilocybin Products
19/04/2022 12:03
April 19 (Reuters) - Filament Health Corp FH.NLB :
* PSYENCE AND FILAMENT HEALTH ENTER INTO EXCLUSIVE LICENSING
AGREEMENT FOR NATURAL PSILOCYBIN PRODUCTS
* PSYENCE GROUP- FILAMENT TO LICENSE ITS PROPRIETARY
BOTANICAL
DRUG CANDIDATE PEX010 (25MG), ASSOCIATED IP TO CO FOR USE IN
CO'S UPCOMING CLINICAL TRIALS
Source text for Eikon: ID:nGNXJRlm3
Further company coverage: FH.NLB
Recent news on Psyence
See all newsBrief: Psyence Group To Consolidate Shares 15 To 1 Effective April 23, 2025
Brief: Psyence Group Enters Into Debt-For-Equity Swap Agreement With Its Nasdaq-Listed Associate, Psyence Biomedical
Brief: Psyence Biomed Enters Into Agreement To Acquire Stake In Psylabs
Brief: Psyence Biomedical Ltd. Approved To List On Nasdaq Following Completion Of Business Combination Agreement With Newcourt Acquisition Corp
MGC Pharmaceuticals - September 2023 Quarter Activity Report